Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference

Vancouver, Canada, July 12, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech...

Shineco Announces Pricing of $2 Million Underwritten Public Offering

Beijing, July 12, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”) (NASDAQ: SISI), a provider of innovative diagnostic medical products...

Top Stories

admin

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual...

Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation Topline Phase 2 ARCHER Trial Results Will be Discussed as an Oral Presentation BRISBANE, Calif., July 11, 2024 (GLOBE NEWSWIRE) --...
admin

Allianz Partners supports Paris 2024 with medical assistance and repatriation services

The 155,000 athletes, volunteers, and members of the Olympic and Paralympic Family will benefit from Allianz Partners' medical assistance and repatriation...

Most Popular

People

Q2 2024 Saw Retail Ecommerce Revenues Rise by 7.2% Amidst Falling...

admin
People

Cosentino Launches Dekton® Pietra Edition, a timeless style collection with Mediterranean...

admin
People

Five Below Brings the Fun to Back-to-School Season on Any Budget

admin
People

Denver Landscaping Lynx Revolutionizes Home Landscaping Services Across Denver’s Front Range...

admin
People

OLAPLEX Strengthens Senior Leadership Team with Key Appointments

admin
admin

37 Interactive Entertainment’s Near term Targets Have Been Validated By SBTi

WASHINGTON, July 9, 2024 /PRNewswire/ -- Recently, 37 Interactive Entertainment's Near Term targets for promoting greenhouse gas emissions reduction have been officially validated by the Science Based Targets initiative (SBTi). The company announced the news on World Environment Day, through their special event Together for a Green and Beautiful Guangzhou....
admin

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s...

SPRING, Texas, July 09, 2024 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., presented today results from studies done on the potential for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease (PD), and Alzheimer’s disease (AD), with its clinical stage experimental therapeutic RXR nuclear receptor agonist compound IRX4204....

Category

Tianjin Advances with AI

admin

Aesthetic procedures close to 35 million in 2023

admin